{
  "success": true,
  "sourceFile": "input/Alexion_NCT04573309_Wilsons_SAP.pdf",
  "pagesUsed": [
    0,
    1,
    2,
    3,
    4,
    5,
    6,
    7,
    8,
    9,
    10,
    11,
    12,
    13,
    14,
    15,
    16,
    17,
    18,
    19,
    20,
    21,
    22,
    23,
    24,
    25,
    26,
    27,
    28,
    29,
    30,
    31,
    32,
    33
  ],
  "modelUsed": "gemini-2.5-pro",
  "sapData": {
    "analysisPopulations": [
      {
        "id": "pop_1",
        "name": "Screened Set",
        "populationType": "Safety",
        "instanceType": "AnalysisPopulation",
        "populationDescription": "The Screened Set will include all participants who signed an informed consent form (ICF)."
      },
      {
        "id": "pop_2",
        "name": "Enrolled Set",
        "populationType": "Safety",
        "instanceType": "AnalysisPopulation",
        "populationDescription": "The Enrolled Set will include all participants who signed an ICF and were enrolled in the study."
      },
      {
        "id": "pop_3",
        "name": "Full Analysis Set",
        "populationType": "Efficacy",
        "instanceType": "AnalysisPopulation",
        "label": "FA",
        "populationDescription": "The Full Analysis (FA) Set will include all participants in the Enrolled Set who received at least 1 dose of study drug and have at least 1 post-Baseline efficacy assessment. The FA Set will be the primary population for all efficacy analyses."
      },
      {
        "id": "pop_4",
        "name": "Per Protocol Set",
        "populationType": "Efficacy",
        "instanceType": "AnalysisPopulation",
        "label": "PP",
        "populationDescription": "The Per Protocol (PP) Set will include all participants in the FA Set who do not have any major protocol deviations that would impact the interpretability of the efficacy data. Major protocol deviations will be identified and agreed upon by the study team prior to database lock. The PP Set will be used for sensitivity analyses of the primary efficacy endpoint."
      },
      {
        "id": "pop_5",
        "name": "Safety Set",
        "populationType": "Safety",
        "instanceType": "AnalysisPopulation",
        "populationDescription": "The Safety Set will include all participants in the Enrolled Set who received at least 1 dose of study drug. The Safety Set will be the primary population for all safety analyses."
      },
      {
        "id": "pop_6",
        "name": "Pharmacokinetic Analysis Set",
        "populationType": "PK/PD",
        "instanceType": "AnalysisPopulation",
        "label": "PK",
        "populationDescription": "The Pharmacokinetic (PK) Analysis Set will include all participants in the Safety Set who have sufficient plasma concentration data to allow for the derivation of at least 1 PK parameter. The PK Analysis Set will be used for all PK analyses."
      },
      {
        "id": "pop_7",
        "name": "Pharmacodynamic Analysis Set",
        "populationType": "PK/PD",
        "instanceType": "AnalysisPopulation",
        "label": "PD",
        "populationDescription": "The Pharmacodynamic (PD) Analysis Set will include all participants in the Safety Set who have sufficient PD data to allow for the derivation of at least 1 PD parameter. The PD Analysis Set will be used for all PD analyses."
      }
    ],
    "characteristics": [],
    "summary": {
      "populationCount": 7,
      "characteristicCount": 0
    }
  }
}